Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.89 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.89 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.89 |
| ▸ | HPGD | P15428 | 6/20 | 0.89 |
| ▸ | MAPT | P10636 | 5/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.89 |
| ▸ | TP53 | P04637 | 4/20 | 0.89 |
| ▸ | PKM | P14618 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.89 |
| ▸ | GAA | P10253 | 3/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.89 |
| ▸ | HTR1A | P08908 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL2256775 | 0.99 | KDM4E (0.89) | KDM4EALDH1A1HPGDDRD2MAPT | |
| Apomorphine SCHEMBL17870681 | 0.97 | KDM4E (0.91) | KDM4EALDH1A1HPGDDRD2MAPT | |
| Apomorphine SCHEMBL1773045 | 0.97 | KDM4E (0.91) | KDM4EALDH1A1HPGDDRD2MAPT | |
| Apomorphine SCHEMBL1923763 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDDRD2MAPT | |
| Apomorphine SCHEMBL29414090 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDDRD2MAPT | |
| Apomorphine SCHEMBL5605456 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDDRD2MAPT | |
| Apomorphine SCHEMBL29599870 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDDRD2MAPT | |
| (S)Apomorphine SCHEMBL6922802 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDDRD2MAPT | |
| Apomorphine SCHEMBL8541 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDDRD2MAPT | |
| (S)Apomorphine SCHEMBL30554804 | 0.94 | KDM4E (1.00) | KDM4EALDH1A1HPGDDRD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993856-A1 | AEROSOL DELIVERY DEVICES AND METHODS OF USING SAME | Airja, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| WO-2021003438-A1 | AEROSOL DELIVERY DEVICES AND METHODS OF USING SAME | AIRJA, INC. (US) | 2021-01-07 | — | — | WO | claimed |
| EP-3746138-A1 | ELECTRICAL CONDENSATION AEROSOL DEVICE | Alexza Pharmaceuticals, Inc. (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2019152873-A1 | ELECTRICAL CONDENSATION AEROSOL DEVICE | ALEXZA PHARMACEUTICALS, INC. (US) | 2019-08-08 | — | — | WO | claimed |
| EP-2608829-A2 | SYSTEMS AND METHODS OF AEROSOL DELIVERY WITH AIRFLOW REGULATION | Rubin, Darren (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012026963-A2 | SYSTEMS AND METHODS OF AEROSOL DELIVERY WITH AIRFLOW REGULATION | RUBIN DARREN (US) | 2012-03-01 | — | — | WO | claimed |
| US-7988952-B2 | Condensation aerosol formed by heating a thin layer containing the ester, on a solid support to produce a vapor of the ester, and condensing; less than 10% ester degradation products by weight, and a Mass median aerodynamic diameter of less than 5 microns | ALEXZA PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20080175796-A1 | Delivery of Drug Esters Through an Inhalation Route | ALEXZA PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | claimed |
| EP-1809240-A2 | CARDIAC SAFE, RAPID MEDICATION DELIVERY | Alexza Pharmaceuticals, Inc. (US) | 2007-07-25 | — | — | EP | claimed |
| US-20060257329-A1 | Delivery of drug esters through an inhalation route | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-11-16 | — | — | US | claimed |
| US-7090830-B2 | Drug condensation aerosols and kits | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-08-15 | — | — | US | claimed |
| US-20060120962-A1 | Cardiac safe, rapid medication delivery | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-08 | — | — | US | claimed |
| WO-2006044421-A2 | CARDIAC SAFE, RAPID MEDICATION DELIVERY | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20040184998-A1 | Delivery of drug esters through an inhalation route | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-09-23 | — | — | US | claimed |
| US-20040156790-A1 | Delivery of drug esters through an inhalation route | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-08-12 | — | — | US | claimed |
| US-20040099269-A1 | Drug condensation aerosols and kits | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2004-05-27 | — | — | US | claimed |
| US-6737042-B2 | AEROSOL COMPRISES PARTICLES COMPRISING AT LEAST 10 PERCENT BY WEIGHT OF A DRUG ESTER. | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-05-18 | — | — | US | claimed |
| EP-1392262-A1 | DELIVERY OF DRUG ESTERS THROUGH AN INHALATION ROUTE | Alexza Molecular Delivery Corporation (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2003026631-A1 | DELIVERY OF DRUG ESTERS THROUGH AN INHALATION ROUTE | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2003-04-03 | — | — | WO | claimed |
| US-20030017115-A1 | Delivery of drug esters through an inhalation route | ALEXZA PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | claimed |